MedTrace Logo

HRV as a Marker of Treatment Response in PAH Arterial Hypertension

NCT04451850 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2025-03-30

No results posted yet for this study

Summary

This is a prospective longitudinal cohort study to determine the value of HRV obtained using noninvasive actigraphy to quantify the response to pulmonary vasodilator therapy in newly diagnosed PAH patients

Conditions

Interventions

OTHER

Noninvasive actigraphy monitor

Noninvasive chest-mounted actigraphic device to be worn for 2 hour intervals two times per week during the six month study participation.

Sponsors & Collaborators

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Arun Jose, MD, MS · University of Cincinnati

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2024-12-01
Completion
2024-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04451850 on ClinicalTrials.gov